Sign In
Buy COYA
$5.29
+0.370 (+7.52%)
At Close: Jun 22, 2026
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
09:00am, Thursday, 18'th Jun 2026
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
08:00am, Thursday, 18'th Jun 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
08:00am, Wednesday, 27'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
07:35am, Tuesday, 12'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:10am, Saturday, 18'th Apr 2026
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One in
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
08:00am, Thursday, 02'nd Apr 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
08:00am, Monday, 16'th Mar 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday
02:30am, Tuesday, 10'th Mar 2026
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Feb 2026
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
